Raymond James & Associates Aptinyx Inc. Transaction History

Raymond James & Associates

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$0.12 - $0.69 $2,328 - $13,385	-19,400 Reduced 42.11%	26,675 $3,000
Q4 2022 Feb 08, 2023	SELL	$0.23 - $0.34 $6,428 - $9,503	-27,950 Reduced 37.76%	46,075 $13,000
Q2 2022 Aug 12, 2022	SELL	$0.38 - $2.58 $6,397 - $43,434	-16,835 Reduced 18.53%	74,025 $41,000
Q1 2022 May 11, 2022	BUY	$2.27 - $3.62 $1,089 - $1,737	480 Added 0.53%	90,860 $206,000
Q4 2021 Feb 08, 2022	SELL	$2.11 - $3.0 $48,424 - $68,850	-22,950 Reduced 20.25%	90,380 $241,000
Q3 2021 Nov 02, 2021	SELL	$2.21 - $2.89 $31,824 - $41,616	-14,400 Reduced 11.27%	113,330 $265,000
Q2 2021 Aug 11, 2021	SELL	$2.39 - $3.5 $43,151 - $63,192	-18,055 Reduced 12.38%	127,730 $361,000
Q1 2021 May 14, 2021	SELL	$2.86 - $4.33 $124,939 - $189,156	-43,685 Reduced 23.06%	145,785 $437,000
Q4 2020 Feb 12, 2021	BUY	$2.93 - $4.3 $417,964 - $613,395	142,650 Added 304.68%	189,470 $656,000
Q3 2020 Nov 04, 2020	BUY	$3.05 - $4.99 $79,666 - $130,338	26,120 Added 126.18%	46,820 $158,000
Q2 2020 Jul 28, 2020	BUY	$1.99 - $4.4 $41,193 - $91,080	20,700 New	20,700 $86,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.